535 related articles for article (PubMed ID: 31348549)
21. Progression in the LRRK2-Asssociated Parkinson Disease Population.
Saunders-Pullman R; Mirelman A; Alcalay RN; Wang C; Ortega RA; Raymond D; Mejia-Santana H; Orbe-Reilly M; Johannes BA; Thaler A; Ozelius L; Orr-Urtreger A; Marder KS; Giladi N; Bressman SB;
JAMA Neurol; 2018 Mar; 75(3):312-319. PubMed ID: 29309488
[TBL] [Abstract][Full Text] [Related]
22. Alzheimer's disease tau is a prominent pathology in LRRK2 Parkinson's disease.
Henderson MX; Sengupta M; Trojanowski JQ; Lee VMY
Acta Neuropathol Commun; 2019 Nov; 7(1):183. PubMed ID: 31733655
[TBL] [Abstract][Full Text] [Related]
23. Motor phenotype of LRRK2-associated Parkinson's disease: a Tunisian longitudinal study.
Nabli F; Ben Sassi S; Amouri R; Duda JE; Farrer MJ; Hentati F
Mov Disord; 2015 Feb; 30(2):253-8. PubMed ID: 25487881
[TBL] [Abstract][Full Text] [Related]
24. Leucine-Rich Repeat Kinase (LRRK2) Genetics and Parkinson's Disease.
Monfrini E; Di Fonzo A
Adv Neurobiol; 2017; 14():3-30. PubMed ID: 28353276
[TBL] [Abstract][Full Text] [Related]
25. LRRK2 expression in idiopathic and G2019S positive Parkinson's disease subjects: a morphological and quantitative study.
Sharma S; Bandopadhyay R; Lashley T; Renton AE; Kingsbury AE; Kumaran R; Kallis C; Vilariño-Güell C; O'Sullivan SS; Lees AJ; Revesz T; Wood NW; Holton JL
Neuropathol Appl Neurobiol; 2011 Dec; 37(7):777-90. PubMed ID: 21696411
[TBL] [Abstract][Full Text] [Related]
26. Serum neurofilament light chain in LRRK2 related Parkinson's disease: A five years follow-up.
Nabizadeh F; Mohamadzadeh O; Hosseini H; Rasouli K; Afyouni NE
J Clin Neurosci; 2023 Apr; 110():12-18. PubMed ID: 36780781
[TBL] [Abstract][Full Text] [Related]
27. Serum Uric Acid in LRRK2 Related Parkinson's Disease: Longitudinal Data from the PPMI Study.
Bougea A; Koros C; Papagiannakis N; Simitsi AM; Prentakis A; Papadimitriou D; Pachi I; Antonelou R; Angelopoulou E; Beratis I; Bozi M; Papageorgiou SG; Trapali XG; Stamelou M; Stefanis L
J Parkinsons Dis; 2021; 11(2):633-640. PubMed ID: 33682725
[TBL] [Abstract][Full Text] [Related]
28. Comparative blood transcriptome analysis in idiopathic and LRRK2 G2019S-associated Parkinson's disease.
Infante J; Prieto C; Sierra M; Sánchez-Juan P; González-Aramburu I; Sánchez-Quintana C; Berciano J; Combarros O; Sainz J
Neurobiol Aging; 2016 Feb; 38():214.e1-214.e5. PubMed ID: 26675812
[TBL] [Abstract][Full Text] [Related]
29. Heart rate variability in leucine-rich repeat kinase 2-associated Parkinson's disease.
Visanji NP; Bhudhikanok GS; Mestre TA; Ghate T; Udupa K; AlDakheel A; Connolly BS; Gasca-Salas C; Kern DS; Jain J; Slow EJ; Faust-Socher A; Kim S; Azhu Valappil R; Kausar F; Rogaeva E; William Langston J; Tanner CM; Schüle B; Lang AE; Goldman SM; Marras C
Mov Disord; 2017 Apr; 32(4):610-614. PubMed ID: 28071824
[TBL] [Abstract][Full Text] [Related]
30.
Garrido A; Fairfoul G; Tolosa ES; Martí MJ; Green A;
Ann Clin Transl Neurol; 2019 Jun; 6(6):1024-1032. PubMed ID: 31211166
[TBL] [Abstract][Full Text] [Related]
31. Carriers of both GBA and LRRK2 mutations, compared to carriers of either, in Parkinson's disease: Risk estimates and genotype-phenotype correlations.
Yahalom G; Greenbaum L; Israeli-Korn S; Fay-Karmon T; Livneh V; Ruskey JA; Roncière L; Alam A; Gan-Or Z; Hassin-Baer S
Parkinsonism Relat Disord; 2019 May; 62():179-184. PubMed ID: 30573413
[TBL] [Abstract][Full Text] [Related]
32. A Possible Modifying Effect of the G2019S Mutation in the LRRK2 Gene on GBA Parkinson's Disease.
Omer N; Giladi N; Gurevich T; Bar-Shira A; Gana-Weisz M; Goldstein O; Kestenbaum M; Cedarbaum JM; Orr-Urtreger A; Mirelman A; Thaler A
Mov Disord; 2020 Jul; 35(7):1249-1253. PubMed ID: 32353202
[TBL] [Abstract][Full Text] [Related]
33. Altered Development of Synapse Structure and Function in Striatum Caused by Parkinson's Disease-Linked LRRK2-G2019S Mutation.
Matikainen-Ankney BA; Kezunovic N; Mesias RE; Tian Y; Williams FM; Huntley GW; Benson DL
J Neurosci; 2016 Jul; 36(27):7128-41. PubMed ID: 27383589
[TBL] [Abstract][Full Text] [Related]
34. Survival rates among Parkinson's disease patients who carry mutations in the LRRK2 and GBA genes.
Thaler A; Kozlovski T; Gurevich T; Bar-Shira A; Gana-Weisz M; Orr-Urtreger A; Giladi N; Mirelman A
Mov Disord; 2018 Oct; 33(10):1656-1660. PubMed ID: 30288804
[TBL] [Abstract][Full Text] [Related]
35. Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study.
Simuni T; Brumm MC; Uribe L; Caspell-Garcia C; Coffey CS; Siderowf A; Alcalay RN; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Nudelman K; Tosun-Turgut D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten S; Bressman S; Marek K;
Mov Disord; 2020 May; 35(5):833-844. PubMed ID: 32073681
[TBL] [Abstract][Full Text] [Related]
36. Prevalence of pre-diagnostic symptoms did not differ between LRRK2-related, GBA-related and idiopathic patients with Parkinson's disease.
Liu SY; Zheng Z; Gu ZQ; Wang CD; Tang BS; Xu YM; Ma JH; Zhou YT; Feng T; Chen SD; Chan P;
Parkinsonism Relat Disord; 2018 Dec; 57():72-76. PubMed ID: 30119933
[TBL] [Abstract][Full Text] [Related]
37. The LRRK2 G2019S mutation is associated with Parkinson disease and concomitant non-skin cancers.
Inzelberg R; Cohen OS; Aharon-Peretz J; Schlesinger I; Gershoni-Baruch R; Djaldetti R; Nitsan Z; Ephraty L; Tunkel O; Kozlova E; Inzelberg L; Kaplan N; Fixler Mehr T; Mory A; Dagan E; Schechtman E; Friedman E; Hassin-Baer S
Neurology; 2012 Mar; 78(11):781-6. PubMed ID: 22323743
[TBL] [Abstract][Full Text] [Related]
38. The effect of LRRK2 mutations on the cholinergic system in manifest and premanifest stages of Parkinson's disease: a cross-sectional PET study.
Liu SY; Wile DJ; Fu JF; Valerio J; Shahinfard E; McCormick S; Mabrouk R; Vafai N; McKenzie J; Neilson N; Perez-Soriano A; Arena JE; Cherkasova M; Chan P; Zhang J; Zabetian CP; Aasly JO; Wszolek ZK; McKeown MJ; Adam MJ; Ruth TJ; Schulzer M; Sossi V; Stoessl AJ
Lancet Neurol; 2018 Apr; 17(4):309-316. PubMed ID: 29456161
[TBL] [Abstract][Full Text] [Related]
39. Cognitive profile and 18F-fluorodeoxyglucose PET study in LRRK2-related Parkinson's disease.
De Rosa A; Peluso S; De Lucia N; Russo P; Annarumma I; Esposito M; Manganelli F; Brunetti A; De Michele G; Pappatà S
Parkinsonism Relat Disord; 2018 Feb; 47():80-83. PubMed ID: 29249679
[TBL] [Abstract][Full Text] [Related]
40. Higher Urine bis(Monoacylglycerol)Phosphate Levels in LRRK2 G2019S Mutation Carriers: Implications for Therapeutic Development.
Alcalay RN; Hsieh F; Tengstrand E; Padmanabhan S; Baptista M; Kehoe C; Narayan S; Boehme AK; Merchant K
Mov Disord; 2020 Jan; 35(1):134-141. PubMed ID: 31505072
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
